WO2006014903A3 - Compositions and methods of use for adam12 antagonists in treating disease - Google Patents

Compositions and methods of use for adam12 antagonists in treating disease Download PDF

Info

Publication number
WO2006014903A3
WO2006014903A3 PCT/US2005/026402 US2005026402W WO2006014903A3 WO 2006014903 A3 WO2006014903 A3 WO 2006014903A3 US 2005026402 W US2005026402 W US 2005026402W WO 2006014903 A3 WO2006014903 A3 WO 2006014903A3
Authority
WO
WIPO (PCT)
Prior art keywords
adam12
cancer
adam12l
demonstrated
normal tissues
Prior art date
Application number
PCT/US2005/026402
Other languages
French (fr)
Other versions
WO2006014903A2 (en
Inventor
Elizabeth Bosch
Kevin Hestir
Ernestine Lee
Haishan Lin
Justin Wong
Original Assignee
Five Prime Therapeutics Inc
Elizabeth Bosch
Kevin Hestir
Ernestine Lee
Haishan Lin
Justin Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Elizabeth Bosch, Kevin Hestir, Ernestine Lee, Haishan Lin, Justin Wong filed Critical Five Prime Therapeutics Inc
Publication of WO2006014903A2 publication Critical patent/WO2006014903A2/en
Publication of WO2006014903A3 publication Critical patent/WO2006014903A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Abstract

Microarray analysis, confirmed by RT-PCT, demonstrated that lung squamous cell carcinoma, colon/colorectal cancer, and breast carcinoma mRNA hybridizes specifically and preferentially to ADAM12L. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridizes specifically to ADAM12. ADAM12L is a transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of ADAM12, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward ADAM12.
PCT/US2005/026402 2004-07-27 2005-07-26 Compositions and methods of use for adam12 antagonists in treating disease WO2006014903A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59152704P 2004-07-27 2004-07-27
US60/591,527 2004-07-27
US67470005P 2005-04-26 2005-04-26
US60/674,700 2005-04-26

Publications (2)

Publication Number Publication Date
WO2006014903A2 WO2006014903A2 (en) 2006-02-09
WO2006014903A3 true WO2006014903A3 (en) 2006-04-20

Family

ID=35385659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026402 WO2006014903A2 (en) 2004-07-27 2005-07-26 Compositions and methods of use for adam12 antagonists in treating disease

Country Status (1)

Country Link
WO (1) WO2006014903A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674597B2 (en) 2004-08-02 2010-03-09 Elan Pharmaceuticals, Inc. Signaling intermediates in an in vitro model of Alzheimer's disease
AU2007210124A1 (en) * 2006-01-26 2007-08-09 The Trustees Of The University Of Pennsylvania Tumor vasculature markers and methods of use thereof
GB2453589A (en) * 2007-10-12 2009-04-15 King S College London Protease inhibition
CA2676946A1 (en) * 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
US8703128B2 (en) 2011-01-24 2014-04-22 New York University Methods of modulating TGFβ signaling
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
AU2020397424A1 (en) 2019-12-05 2022-06-09 Bcn Peptides, S.A. Peptides for the treatment of cancer and/or metastasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040072A2 (en) * 1996-04-19 1997-10-30 The University Of Sheffield Adam proteins and uses thereof
EP0933423A1 (en) * 1996-02-23 1999-08-04 Mochida Pharmaceutical Co., Ltd. Meltrins
US20040002467A1 (en) * 2002-06-29 2004-01-01 Isis Pharmaceuticals Inc. Antisense modulation of ADAM12 expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933423A1 (en) * 1996-02-23 1999-08-04 Mochida Pharmaceutical Co., Ltd. Meltrins
WO1997040072A2 (en) * 1996-04-19 1997-10-30 The University Of Sheffield Adam proteins and uses thereof
US20040002467A1 (en) * 2002-06-29 2004-01-01 Isis Pharmaceuticals Inc. Antisense modulation of ADAM12 expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUOVILA A-P J ET AL: "ADAMS AND CELL FUSION", CURRENT OPINION IN CELL BIOLOGY, CURRENT SCIENCE, LONDON, GB, vol. 8, no. 5, October 1996 (1996-10-01), pages 692 - 699, XP002044203, ISSN: 0955-0674 *

Also Published As

Publication number Publication date
WO2006014903A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2006014903A3 (en) Compositions and methods of use for adam12 antagonists in treating disease
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2008077077A3 (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
EP2518163A3 (en) Prostate cancer specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2009050691A3 (en) Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
WO2007015935A8 (en) Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2005000087A3 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2006044486A3 (en) Methods and compositions for the utilization and targeting of osteomimicry
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase